Glaukos Corporation $GKOS Shares Newly Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new position in shares of Glaukos Corporation (NYSE:GKOS) during the third quarter, HoldingsChannel reports. The firm purchased 44,100 shares of the medical instruments supplier’s stock, valued at approximately $7,241,000. Glaukos comprises 1.9% of Lisanti Capital Growth LLC’s portfolio, making the stock its 8th biggest position.

Other large investors have also recently added to or reduced their stakes in the company. Fulcrum Asset Management LLP lifted its position in Glaukos by 91.7% in the third quarter. Fulcrum Asset Management LLP now owns 184 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 88 shares during the period. Allworth Financial LP purchased a new stake in Glaukos in the 2nd quarter valued at approximately $28,000. CoreCap Advisors LLC purchased a new stake in Glaukos in the 3rd quarter valued at approximately $33,000. Fortitude Family Office LLC acquired a new position in Glaukos during the 3rd quarter worth approximately $36,000. Finally, Provenance Wealth Advisors LLC acquired a new position in Glaukos during the 3rd quarter worth approximately $44,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $247.80 on Thursday. The company has a current ratio of 4.57, a quick ratio of 4.09 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52 week low of $87.32 and a 52 week high of $255.18. The firm has a 50-day moving average price of $181.98 and a 200 day moving average price of $145.86.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The firm had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. The firm’s revenue was up 58.0% on a year-over-year basis. Research analysts predict that Glaukos Corporation will post 0.50 EPS for the current year.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of analyst reports. Wells Fargo & Company increased their target price on Glaukos from $178.00 to $226.00 and gave the stock an “overweight” rating in a research note on Thursday, October 29th. Needham & Company LLC raised their price target on Glaukos from $201.00 to $251.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Jefferies Financial Group lifted their price target on Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, September 22nd. BTIG Research upped their price objective on Glaukos from $205.00 to $234.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Finally, Citigroup increased their price objective on Glaukos from $225.00 to $247.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $216.71.

Insider Buying and Selling at Glaukos

In related news, Director Gilbert Kliman sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total value of $632,500.00. Following the sale, the director owned 37,406 shares in the company, valued at $9,463,718. This represents a 6.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.